Search results
CRSP’s unique historical indexes serve as benchmarks for the investment community and as a foundation for academic research. Created according to clear and unbiased methodologies, these indexes undergo rigorous review to ensure data accuracy, timeliness, and consistency. Stock File Indexes. Cap-Based Portfolios. Indexes for the S&P 500 Universe.
Corporate actions. Identifiers, descriptors, and supplemental data items. CRSP's rigorous analysis for accuracy and unique research source is characterized by its unmatched breadth, depth, and completeness — providing unique permanent identifiers backtesting, time series and event studies, and measurement of performance. Corresponding Slide Deck.
4 days ago · The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person. The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million. Other symbols: VRTX.
Total cash and short-term investments (that can quickly be turned into cash) minus total debt. If it's positive, the company has more cash than debt, and vice versa if it is negative. Don't assume ...
The CRSP US Treasury and Inflation Series is comprised of 1.7 million end-of-day price observations for nearly 7000 US Treasury bills, notes, and bonds, as well as many supplemental files. Supplemental files include fixed-term indexes, maturity portfolios, discount bonds, term structure and CPI files. The database begins in 1925 for month-end ...
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well. ZUG ...
52 Week Low 37.55. 52 Week Low Date 10/23/23. Market Cap 4.523B. Shares Out 84.88M. 10 Day Average Volume 1.27M. Dividend -. Dividend Yield -. Beta 1.79. YTD % Change -14.87.
